Comment
Author: Admin | 2025-04-28
Experimental research study, and/or known allergy to either albendazole or ivermectin. Weight, height, and dose pole categories based on height were recorded in individual case report forms. Additionally, the children’s temperature was also measured and documented; children who had a fever (≥ 38°C) underwent a malaria rapid diagnostic test. A positive result would lead to exclusion from the randomization and treatment. Finally, a physician assessed their health to ensure eligibility.Enrolment and drug administration were overseen by the study team. Children were assigned to receive either albendazole alone (400 mg tablet) or the combination of albendazole (400 mg) and ivermectin (200 μg/kg approximated by dose pole height category). In Kahungye primary school, all children had received food prior to treatment, whereas in the Rwanzu primary school they received food one hour post-treatment. Physicians and nurses actively queried each participant for adverse events using a questionnaire at three and 24 hours post-treatment.During follow-up, conducted between 14 and 21 days after treatment, each participant was requested to provide two additional stool samples. Follow-up samples were also collected at school, if possible on two consecutive days, and underwent the same procedures as described for baseline samples. Participants still found infected with any STH at follow-up were treated with the combination of albendazole (400 mg) and ivermectin (200 μg/kg).EndpointsThe primary endpoint of this trial was T. trichiura infection status of participants 14–21 days post-treatment assessed by duplicate Kato-Katz thick smears. Secondary endpoints were T. trichiura intensity of infection (egg reduction rate (ERR)) 14–21 days post-treatment
Add Comment